Pluri Past Earnings Performance
Past criteria checks 0/6
Pluri has been growing earnings at an average annual rate of 0.3%, while the Biotechs industry saw earnings growing at 12.1% annually. Revenues have been growing at an average rate of 54.1% per year.
Key information
0.3%
Earnings growth rate
25.7%
EPS growth rate
Biotechs Industry Growth | -24.5% |
Revenue growth rate | 54.1% |
Return on equity | -369.6% |
Net Margin | -6,708.4% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Pluri makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -24 | 11 | 14 |
30 Sep 23 | 0 | -27 | 11 | 14 |
30 Jun 23 | 0 | -28 | 12 | 16 |
31 Mar 23 | 0 | -31 | 13 | 16 |
31 Dec 22 | 0 | -33 | 14 | 20 |
30 Sep 22 | 0 | -36 | 15 | 22 |
30 Jun 22 | 0 | -41 | 17 | 24 |
31 Mar 22 | 0 | -47 | 21 | 27 |
31 Dec 21 | 0 | -51 | 23 | 28 |
30 Sep 21 | 0 | -53 | 24 | 29 |
30 Jun 21 | 0 | -50 | 22 | 29 |
31 Mar 21 | 0 | -43 | 18 | 27 |
31 Dec 20 | 0 | -37 | 13 | 25 |
30 Sep 20 | 0 | -31 | 10 | 21 |
30 Jun 20 | 0 | -29 | 9 | 21 |
31 Mar 20 | 0 | -29 | 8 | 21 |
31 Dec 19 | 0 | -31 | 8 | 23 |
30 Sep 19 | 0 | -34 | 9 | 25 |
30 Jun 19 | 0 | -35 | 9 | 26 |
31 Mar 19 | 0 | -37 | 11 | 26 |
31 Dec 18 | 0 | -28 | 11 | 24 |
30 Sep 18 | 0 | -28 | 12 | 24 |
30 Jun 18 | 0 | -26 | 11 | 23 |
31 Mar 18 | 0 | -24 | 11 | 20 |
31 Dec 17 | 0 | -30 | 11 | 20 |
30 Sep 17 | 0 | -29 | 9 | 20 |
30 Jun 17 | 0 | -28 | 8 | 20 |
31 Mar 17 | 0 | -27 | 8 | 20 |
31 Dec 16 | 0 | -26 | 7 | 19 |
30 Sep 16 | 3 | -24 | 8 | 19 |
30 Jun 16 | 3 | -23 | 8 | 19 |
31 Mar 16 | 3 | -22 | 7 | 18 |
31 Dec 15 | 3 | -22 | 7 | 19 |
30 Sep 15 | 0 | -25 | 7 | 18 |
30 Jun 15 | 0 | -25 | 7 | 18 |
31 Mar 15 | 0 | -26 | 8 | 19 |
31 Dec 14 | 0 | -28 | 9 | 19 |
30 Sep 14 | 0 | -28 | 9 | 19 |
30 Jun 14 | 0 | -27 | 10 | 19 |
31 Mar 14 | 0 | -28 | 9 | 20 |
31 Dec 13 | 0 | -24 | 7 | 18 |
30 Sep 13 | 1 | -22 | 7 | 17 |
30 Jun 13 | 1 | -21 | 7 | 16 |
Quality Earnings: PLUR is currently unprofitable.
Growing Profit Margin: PLUR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PLUR is unprofitable, but has reduced losses over the past 5 years at a rate of 0.3% per year.
Accelerating Growth: Unable to compare PLUR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PLUR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.4%).
Return on Equity
High ROE: PLUR has a negative Return on Equity (-369.59%), as it is currently unprofitable.